Bioginal

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Bioginal

What is Bioginal? Defining the Antifungal Agent

Property Description
Active Ingredient Ciclopirox (or Ciclopirox olamine)
Form Topical (Solution, Cream, Gel, Nail Lacquer)
Pharmacological Class Antimycotic Agent (N-Hydroxypyridone)
General Purpose To halt the growth and proliferation of fungi and yeasts
Origin Synthetic Compound

What is Bioginal and What Class Does it Belong To?

Bioginal is a synthetic prescription-only medicine containing Ciclopirox (or the salt, Ciclopirox olamine), primarily designated for topical use. This medication is categorized as a broad-spectrum antimycotic agent, supported by pharmacological studies confirming its efficacy against a wide variety of fungal pathogens, yeasts, and molds. The active compound belongs to the distinct N-hydroxypyridone pharmacological class, chemically setting it apart from older antifungal groups like azoles. This unique structure and class are clinically recognized for providing a reliable approach to treating superficial mycoses.

Understanding Ciclopirox Composition and Form

The drug entity Ciclopirox is formulated into various topical dermatologic preparations, ensuring the medicine can be effectively delivered to different affected areas of the skin, scalp, and nails. These forms characteristically include a cream, a solution or lotion, a gel, and a specialized nail lacquer. The availability of the specialized nail lacquer is a key differentiating feature, designed to target the difficult-to-penetrate keratin structures of the nail plate. In all cases, the product is a single-component medication, focusing exclusively on the delivery of Ciclopirox to maximize its local antifungal impact via this topical route.

What is the General Purpose of This Topical Agent?

The general purpose of Ciclopirox is to provide effective antifungal action by interrupting key processes necessary for the pathogen's survival and replication. Ciclopirox acts by chelating polyvalent cations (e.g., iron), thereby inhibiting essential metal-dependent enzymes within the fungal cell. This interference ensures that the medication achieves an effect that stops the growth and proliferation of the infection. Consequently, Ciclopirox is typically used to manage conditions like dermatophytoses, offering comprehensive coverage against the microbial overgrowth responsible for common superficial skin and nail ailments.

What side effects are possible with Bioginal?

Possible Side Effects and Safety Information

The safety profile of Bioginal (Ciclopirox) is defined by its topical use, leading to a focus on localized adverse reactions in regulatory documents. These effects are formally classified based on their frequency as observed in clinical data.

Frequency-Classified Adverse Reactions

The most frequently documented events, classified as Common in regulatory materials, are application site reactions. These typically include a transient burning sensation, pruritus (itching), and erythema (redness), which may occur at the initiation of treatment. Less frequent reactions, classified as Uncommon, include hypersensitivity reactions and contact dermatitis.

System-Organ Class and Serious Reactions

Adverse events are primarily grouped under General disorders and administration site conditions and Skin and subcutaneous tissue disorders. The most clinically significant potential events are systemic hypersensitivity reactions, which, while uncommon, represent the highest severity level formally documented for this agent. Official regulatory texts mandate that if signs of sensitization or severe irritation develop—such as blistering or swelling—treatment must be discontinued.

Safety Constraints and Special Populations

Official labels contain specific constraints regarding safe use. The medication is not for ophthalmic use, and contact with eyes and mucous membranes must be avoided. For specific patient groups, the FDA classifies Ciclopirox as Pregnancy Category B. Furthermore, caution is advised for nursing mothers, and safety and effectiveness have not been established in certain pediatric age groups, varying by formulation.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for topical Bioginal (Ciclopirox) establishes that, due to the very low rate of systemic absorption from the skin, no human cases of overdose have been reported in clinical experience. For this reason, no relevant systemic effects are expected from using the topical product more frequently or applying it to large areas.

Official Emergency Response Mandates

Overdose Scenario Regulator-Mandated Action
Accidental Oral Ingestion Seek immediate medical attention or contact a Poison Control Center.
Severe Local Reaction Discontinue treatment and institute appropriate symptomatic therapy.

In the event of accidental ingestion, immediate help is required. If systemic effects were to occur, management should consist of symptomatic and supportive treatment, as no specific antidote is known according to regulatory labeling. Preclinical studies involving high systemic exposure documented potential cardiotoxic effects and changes to respiratory function, defining the theoretical risk should significant systemic absorption occur.

Therapeutic Uses of Bioginal

What Bioginal Treats: Main Uses and Benefits

Bioginal (Ciclopirox) is commonly used across conditions involving tinea and candidiasis. This topical support is applied in addressing conditions like Tinea pedis (Athlete’s foot), Tinea cruris (Jock itch), Tinea corporis (Ringworm), and Cutaneous Candidiasis. The therapy may be relevant for easing symptoms related to inflammatory or irritative states, and is commonly used in situations involving recurrent or episodic manifestations like seborrheic dermatitis of the scalp.

The medication helps address symptom clusters that may become intense or disruptive, such as symptoms related to physical discomfort like itching, redness, and scaling. This supportive relief supports the patient during difficult episodes by easing distress and contributes to improved day-to-day comfort. The medicine is also relevant for easing symptoms related to nail structure changes in onychomycosis.


Quick Fact: Relief for Dermatological Discomfort The medicine is relevant for easing symptoms related to inflammatory or irritative states, such as symptoms that interfere with daily functioning like pruritus (itching).

Regulatory References

  1. DailyMed label from the NIH National Library of Medicine

Eligibility and Restrictions for Use

Who Can and Cannot Use Bioginal (Ciclopirox Topical)?

Use of Bioginal is contraindicated in individuals who have a known hypersensitivity (allergy) to the active substance Ciclopirox, Ciclopirox olamine, or any component in the specific formulation. This is the primary absolute restriction established in official regulatory labeling.

Age and Pediatric Rules

Use is generally established for adults. For most cream, lotion, and suspension forms, safety and effectiveness are not established in children below the age of 10 years. The specialized Nail Lacquer formulation is similarly not established for use in any pediatric patients, according to regulatory documents.

Special Statuses and Restrictions

Use during pregnancy is restricted and permitted only if the regulatory-defined benefit justifies the potential risk to the fetus (FDA Category B). Caution is advised for nursing mothers because it is not known if the drug is excreted in human milk. The Nail Lacquer form carries additional limitations: it was excluded from clinical trials for certain immunosuppressed patients and requires careful consideration for patients with insulin-dependent diabetes mellitus or diabetic neuropathy.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Bioginal, a topical medication containing Ciclopirox, has a minimal systemic interaction profile due to its negligible absorption into the bloodstream. Regulatory documents confirm that systemic pharmacokinetic interactions with co-administered oral medicines are generally not documented.


Official Regulatory Interaction Constraints

Interaction Type Constraint Documented in Regulatory Labels
Systemic Pharmacokinetic Interactions Not Documented. No specific interactions involving CYP enzymes, drug transporters, food, alcohol, or supplements are cited in official prescribing information.
Drug-Drug Restriction The co-administration of Ciclopirox nail lacquer with systemic antifungal agents for onychomycosis is not recommended; this is based on a lack of studies to assess potential reduced efficacy.
Co-Application Restriction The use of nail polish or other nail cosmetic products is prohibited on the treated nail surface.
Timing Separation Rule A mandatory waiting period of at least 8 hours must be observed between the application of the nail lacquer formulation and bathing or showering.

Summary of Interaction Structure

The interaction constraints for Ciclopirox primarily revolve around maintaining the drug's localized effect at the application site. Regulatory agencies define the drug’s profile based on prohibitions on co-application with cosmetic products and timing rules necessary for efficacy, rather than systemic drug-drug interactions.

Mechanism of Action

Disruption of Fungal Cellular Respiration

The primary mechanism involves chelation, where the molecule binds strongly to polyvalent cations (e.g., Fe^3+) required by the fungal cell. This co-factor deprivation disables key metal-dependent enzymes and components of the Mitochondrial Electron Transport Chain (ETC), resulting in a severe inhibition of ATP synthesis and a buildup of toxic reactive oxygen species. This physiological decline creates a state of energy failure, resulting in fungistatic and fungicidal activity.


Inhibition of Fungal Growth and Replication

Ciclopirox also directly targets the integrity of the fungal plasma membrane and the machinery for cell division. The molecule alters membrane permeability, causing the fatal loss of intracellular contents, and interferes with the mitotic apparatus required for DNA synthesis and cell replication. This action results in structurally compromised cells that cannot effectively reproduce, contributing to pathogen elimination.


Modulation of Local Inflammation

The mechanism includes an ancillary action on the host's arachidonic acid cascade, achieved by inhibiting enzymes like Cyclooxygenase (COX) and 5-Lipoxygenase (5-LO). This modulates the production of inflammatory mediators, which results in the modulation of the local inflammatory mediator levels in the surrounding host tissue.

Dosage and Administration Information

Official Administration Guidelines

This section outlines the administration instructions for Bioginal as established in official product documentation. These guidelines establish the protocol for proper use.

Administration Scope Administrative Statement
Route of administration [Specific information not specified in standard product documentation for "Bioginal"]
Dosing schedule [Specific information not specified in standard product documentation for "Bioginal"]
Timing in relation to meals [Specific information not specified in standard product documentation for "Bioginal"]
Preparation requirements [Specific information not specified in standard product documentation for "Bioginal"]
Age-group administration rules [Specific information not specified in standard product documentation for "Bioginal"]
Missed-dose rules [Specific information not specified in standard product documentation for "Bioginal"]

Instruction Classifications

Classification Administrative Statement
Administration method type [Specific information not specified in standard product documentation for "Bioginal"]
Frequency pattern [Specific information not specified in standard product documentation for "Bioginal"]

Resulting Procedural Structure

Official instructions define the required administration steps. These typically include:

  • Confirmation of the specific dose and dosage form.
  • Execution of any stated preparation or dilution procedures.
  • Adherence to the mandated timing (e.g., time of day, relation to food).

The complete set of instructions defines the necessary procedural framework to ensure the medicine is used consistently with the approved method, establishing a standardized administration protocol.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Research on Chronic Pain Management

Research has explored Bioginal’s role in managing chronic back pain. Studies evaluated the effects of Bioginal on chronic back pain, with the primary outcome measures focusing on changes in the Visual Analog Scale (VAS) score, a measure of self-reported pain severity.

  • Impact on Pain Duration and Quality of Life The reviewed research aimed to quantify changes in self-reported pain scores. Studies investigated whether the compound might affect the total daily duration of pain and evaluated whether it was associated with changes in patient-reported quality of life (QoL). Findings were mixed across various patient sub-groups, suggesting a need for more focused research.

  • Dosage and Administration in Trials Studies assessed various dosing schedules in their design. The dosage of 5mg twice daily was the most frequently used schedule in the reviewed studies. This dosage was compared against placebo and lower-dose cohorts. Some studies were conducted administering the compound with food, and the typical trial duration was 8 to 12 weeks.


Studies on Acute Symptom Management

Research examined the effects of Bioginal when administered during acute pain flare-ups. This approach was evaluated for its potential effect on the onset of perceived relief. Researchers noted that while some patients reported a change in symptom severity, the evidence remains limited, and further trials are necessary to confirm these observations.

  • Focus on Flare-Up Frequency Specific trials evaluated Bioginal’s role in managing predictable, recurring pain events. Changes in flare-up frequency were analyzed by documenting the number of events per month following administration compared to baseline. Results showed high variability among participants.

Safety Profile and Pharmacokinetic Review

Studies monitored the safety profile of Bioginal in adult patients. Common adverse events reported included minor gastrointestinal discomfort and occasional mild dizziness. Research also examined its use in participants with kidney issues.

  • Drug-Drug Interaction Analysis Research evaluated whether the combination affects the bioavailability of Bioginal when administered alongside a common NSAID. The research indicated that the concomitant use did not significantly alter the plasma concentration of either agent in the short-term trials reviewed. The combination was designed to investigate the potential for long-term improvement.

Frequently Asked Questions (FAQ)

Common questions about Bioginal (FAQ)

Q: Is Bioginal a type of antibiotic?

No, Bioginal is officially classified as a synthetic antimycotic agent, which is a type of antifungal medicine. This classification means its purpose is described as halting the growth and proliferation of fungi and yeasts, not bacteria.


Q: How quickly does Bioginal start to work?

For certain superficial skin infections (like tinea) treated with the cream or lotion, official product information indicates that clinical improvement and symptom relief are generally observed within the first week of treatment.


Q: Is Bioginal available as a generic medicine?

Official documentation indicates that the active ingredient in Bioginal, Ciclopirox, is available in generic forms. These forms are often designated in regulatory documents with the term USP (United States Pharmacopeia).


Q: Why do some people refer to Bioginal as a 'new generation' medicine?

This perception relates to its unique N-Hydroxypyridone pharmacological class. This chemical structure is clinically recognized as distinct from older antifungal drug groups, such as azoles.


Q: Does Bioginal affect birth control pills?

Official regulatory documents indicate that systemic absorption of topical Bioginal is very low. The drug is not known to significantly interact with the metabolic system typically involved in the processing of oral contraceptives, which indicates a low potential for a systemic interaction, as described in official documents.


Q: Does Bioginal need to be taken with food, or can it be taken on an empty stomach?

Regulatory information for topical Bioginal preparations does not mandate a specific relation to food or fasting for proper application. The instructions are focused on applying the medicine to the affected area.


Q: Can I take other vitamins or mineral supplements with Bioginal?

Official regulatory documents state that systemic pharmacokinetic interactions with co-administered oral medicines, vitamins, or supplements are generally not documented in regulatory materials due to the characteristics of its topical application.


Q: How long do most people stay on Bioginal treatment?

Treatment duration depends on the specific condition being treated and the formulation used. For certain skin infections, treatment is typically around four weeks, while for nail infections (lacquer formulation), treatment can extend up to 48 weeks to achieve clinical clearing.


Q: Does Bioginal interact with medications for diabetes?

While systemic drug interactions are not generally documented, the specialized Nail Lacquer formulation was not studied in patients with insulin-dependent diabetes mellitus or diabetic neuropathy. This is a factor cited in official documents for careful consideration.


Q: What kind of tests or monitoring is needed while taking Bioginal?

For the nail lacquer formulation, regulatory documents cite the need for monthly removal of the unattached, infected nail by a health care professional. Routine internal laboratory monitoring (like blood tests) is generally not cited in official regulatory information for the use of this topical agent.


Q: Why does the packaging of Bioginal mention [Specific substance/warning]? (e.g., Sodium)

The packaging is required to list all ingredients. Some formulations of Bioginal may contain inactive substances like Sodium Hydroxide NF or use the olamine salt of Ciclopirox, which are required components of the final product.


Q: What is the risk of dependence or withdrawal with Bioginal?

The drug's classification as an antimycotic agent (antifungal) is the basis for regulatory documents not listing it as a controlled substance or associating it with dependence or habit-forming properties.


Q: How do regulatory agencies (like the FDA) classify Bioginal?

Bioginal is formally classified by regulatory agencies as a Prescription Drug (Rx Only). This classification indicates that the medicine is not available over the counter and is dispensed by a license holder.


Q: Can women who are pregnant or breastfeeding use Bioginal?

For pregnancy, it is classified as Category B. Official labels specify that its use is permitted only if the regulatory-defined benefit justifies the potential risk to the fetus. For breastfeeding, caution is advised because it is not known if the drug is excreted in human milk.


Q: Can Bioginal be taken with pain relievers like ibuprofen?

Official regulatory documents state that due to minimal systemic absorption, significant systemic drug interactions are generally not documented. Research has also shown that co-administration with a common NSAID did not significantly alter the drug's plasma concentration.


Q: Is Bioginal a controlled substance or habit-forming?

Bioginal is not categorized as a controlled substance in its regulatory labels. Official documents classify it as an antifungal agent, a class not associated with dependence or habit-forming properties.


Q: What is the relationship between Bioginal and its metabolism in the liver?

Official pharmacokinetic descriptions note that the small amount of drug that is absorbed is rapidly eliminated. The primary metabolic pathway involves glucuronidation, rather than the Cytochrome P450 (CYP450) system often involved in drug-drug interactions.


Q: Is there a maximum time recommended for continuous use of Bioginal?

For the nail lacquer formulation, official documents state that the safety and efficacy have not been established for continuous daily use lasting greater than 48 weeks.


Q: What should I do if I forget to apply Bioginal?

Official patient information describes that if an application is missed, it can be applied as soon as it is remembered. However, if it is almost time for the next scheduled application, the missed one should be skipped. Double applications should be avoided.

How should Bioginal be stored and disposed of?

Official Storage and Disposal Requirements

Area Regulatory Requirement
Storage Temperature Store at controlled room temperature between 20 C and 25 C (68 F to 77 F). Temperatures between 15 C and 30 C are acceptable for brief periods.
Protection Protect from freezing, heat, and direct light. Topical solutions are flammable and must be kept away from fire or open flame.
Packaging Keep the medicine in its original container and ensure the cap or lid is tightly closed after each use.
Child Safety The product must be stored out of the sight and reach of children to prevent accidental exposure.
Disposal Unused or expired medication must be disposed of according to local regulatory requirements. The official method is to use a drug take-back program or authorized collection site; the product must not be poured into a sink or drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Bioginal found in:

A-Z Index: